TerminatedPhase 2NCT04391309

COVID-19 and Anti-CD14 Treatment Trial

Studying Severe acute respiratory syndrome

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Principal Investigator
Mark M. Wurfel, MD, PhD
University of Washington: Division of Pulmonary, Critical Care and Sleep Medicine
Intervention
anti-CD14(biological)
Enrollment
49 target
Eligibility
18 years · All sexes
Timeline
20212022

Study locations (5)

Collaborators

University of Washington · Implicit Bioscience · Vanderbilt University Medical Center · PPD Development, LP

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT04391309 on ClinicalTrials.gov

Other trials for Severe acute respiratory syndrome

Additional recruiting or active studies for the same condition.

See all trials for Severe acute respiratory syndrome

← Back to all trials